Source - LSE Regulatory
RNS Number : 6751M
Oncimmune Holdings PLC
25 January 2021

25 January 2021


Oncimmune Holdings plc


("Oncimmune" or the "Company")


Notice of Half Year Results


Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, will be announcing its half year results for the six months ended 30 November 2020 on Monday, 15 February 2021.


Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.


For conference call details please contact Alexander Davis of FTI Consulting at or 020 3727 1000.


The management team will also host on Investor Meet Company a live presentation of the results on Monday, 15 February 2021 at 16:30 GMT.


•     The online presentation will be open to all existing shareholders and potential new investors.


•     Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the "Ask a Question" function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.


•     Investor feedback can also be submitted directly to management immediately following the event.


Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link:


Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.


For further information:


Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer


Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000


N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000


WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321


Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

+44 (0)20 3727 1000


About Oncimmune


Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.


Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.


Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. ​Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.


Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.


For more information, visit

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.